Cinacalcet treatment enhances in vivo homing, lodgment, and engraftment. (A) Cinacalcet- or control-treated LK cells were labeled with green or red membrane fluorescent dyes, respectively. The percentage of labeled cells present in the BM after transplantation was determined by flow cytometric analysis. Representative flow plots (left) and percentage of labeled cells present in the BM (right) are shown (*P < .05; n = 4 from 4 independent experiments). (B) Spleen cells from each recipient mouse were obtained, and homing was analyzed as for BM cells. (C) Quantification of the percentage of LK cells labeled with CFSE (Cinacalcet) or SNARF (control) present in the BM within 2 cell diameters of the endosteal surface in femoral and tibial sections. A representative picture of the anatomical localization of a CFSE⁺ LK cell (green) at the endosteal region and a SNARF⁺ LK cell (red) away from the endosteal region is shown. Cells were also stained with 4′,6-diamidino-2-phenylindole (blue) present in Vectashield (***P < .002; n = 180 sections from 3 independent experiments.). (D) Competitive repopulation of CD45.1 donor LKS⁺F⁻ cells (Cinacalcet or control) and CD45.2 BM MNCs was analyzed by flow cytometric analysis on peripheral blood samples obtained from the recipient mice (*P < .05; n = 9 from 2 independent experiments; error bars represent SEMs).